Blue-Light Glasses for Mania: The Best Trial Found No Benefit

Amber glasses have a plausible mechanism. They do not yet have proof for mania.

Blue-light blocking glasses are often sold as a simple way to protect sleep: put on amber lenses at night, reduce the wavelengths that tell the brain it is daytime, and let melatonin do its job. That biology is real. The leap from "may preserve a nighttime signal" to "treats bipolar mania" is not.

The strongest test so far, the 2026 Ottawa Sunglasses at Night randomized trial, found no antimanic benefit from amber blue-blocking glasses in hospitalized patients with acute mania. After two weeks, the difference in Young Mania Rating Scale (YMRS) scores was 2.1 points in favor of the lightly tinted control-glasses group, not the blue-blocking group. The group-by-time interaction had a p value of 0.93. That result does not show that the glasses help acute mania under the conditions tested.

This is a useful correction to a seductive story. Circadian disruption matters in bipolar disorder, and light is one of the body's strongest timing cues. But a biologically sensible intervention still has to improve patient outcomes in a fair clinical test. These glasses have not cleared that bar for acute mania.

Why blue light became a treatment candidate

Human circadian timing depends heavily on light reaching specialized retinal cells called intrinsically photosensitive retinal ganglion cells. These cells contain melanopsin, which is especially sensitive to short-wavelength light near 480 nm and sends timing signals to the brain's master clock, the suprachiasmatic nucleus. Evening or nighttime short-wavelength light can suppress melatonin and shift circadian timing.

A 2022 controlled laboratory study by St Hilaire et al. mapped how human circadian phase resetting and melatonin suppression respond to different wavelengths and exposure durations. It supports the basic idea behind amber lenses: reduce relevant evening light, and you may reduce the light signal that suppresses melatonin.

The same study also complicates the usual marketing diagram. Spectral sensitivity changed with exposure duration. With longer exposures, rods and cones contributed more to the response, reducing the clean wavelength specificity implied by a melanopsin-only model. An amber lens is not a remote control for melatonin, and "blocks blue light" does not tell you how much circadian effect it will produce in a particular room, at a particular time, for a particular person.

Those laboratory data came from healthy adults under controlled conditions. They do not establish that people in manic states have the same retinal sensitivity, clock response, or melatonin rhythm as healthy participants. They establish a mechanism worth testing, not a treatment effect.

The Ottawa trial tested the clinical claim directly

The Ottawa study used the design that matters most for a claim about acute mania: a randomized, controlled, blinded inpatient trial. Researchers assigned 42 hospitalized participants with acute mania to amber blue-blocking glasses (20 people) or lightly tinted control glasses (22 people), worn during evening hours for two weeks. The main clinical outcome was change in YMRS score.

Both groups received substantial and similar medication exposure. Mean antipsychotic use was 7.2 mg/day risperidone equivalents in the blue-blocking group and 7.1 mg/day in the control group; the reported p value for that comparison was 0.29. Lorazepam equivalents were 0.7 mg/day in both groups, with p=0.67. Medication was not optional background noise here. Treating acute mania promptly is an ethical requirement.

At week two, however, the glasses did not add a detectable benefit. The 2.1-point YMRS difference favored the control group, and p=0.93 for the group-by-time interaction offers no statistical signal that the two trajectories differed. A nonsignificant result alone can reflect limited precision; the direction of the observed difference also gives no reason to recast this trial as a near-success.

The study was small, and 42 participants may not be enough to detect a modest clinical effect on top of intensive pharmacologic treatment. That limitation should temper claims that the trial has disproved every possible use of blue-blocking lenses. It does not support the opposite claim either. For hospitalized acute mania treated over two weeks, the trial found no evidence that these glasses improved symptoms beyond lightly tinted control lenses.

Why a null trial may still leave questions

Several design issues limit what the Ottawa result can settle. The publication does not provide a spectral transmission curve for the lightly tinted control lenses. If those lenses blocked a meaningful amount of short-wavelength light, the comparison may have reduced the difference between groups. The ward's ambient light exposure is also not documented in the available report. A hospital environment may provide less variable or lower-intensity evening light than home life, leaving less blue light for either lens to block.

Neither issue turns the result into evidence of benefit. They identify what a better trial should measure: the spectrum and intensity of ambient light, the transmission of both lens types, adherence, and objective circadian outcomes such as dim-light melatonin onset or actigraphy-derived timing.

Those measures matter because symptom improvement and target engagement are different questions. A trial can show that glasses alter melatonin timing without showing that they reduce manic symptoms. Conversely, if a trial does not measure circadian timing, it cannot tell whether a negative symptom result occurred because the circadian target was never shifted or because shifting it did not help the illness.

The broader bipolar evidence remains thin

A 2022 systematic review by Bisdounis et al. found only two randomized controlled trials of blue-light blocking in bipolar disorder. The studies were too heterogeneous to pool, so there is no reliable summary effect estimate for the intervention. The review also found that 10 of 19 randomized circadian-intervention trials did not measure sleep or circadian outcomes objectively. That leaves a large target-engagement gap across this area of research.

Blue-light blocking should not be confused with bright light therapy. In the same review, six randomized trials of bright light therapy for bipolar depression could be pooled. The estimated effect was Hedges' g=-0.74, with a 95% confidence interval from -1.05 to -0.42 and p<0.001. That is a meaningful evidence advantage for bright light therapy in bipolar depression, not evidence that it treats mania or that amber glasses work by the reverse logic.

The distinction matters clinically. Light interventions depend on timing, intensity, wavelength, and the phase of bipolar illness. A treatment that helps depressive symptoms in one setting cannot be assumed to calm acute mania in another. Circadian biology has more knobs than an app setting.

Could outpatient maintenance be different?

Possibly, but that remains a research question. The BLUES trial protocol, published by Madsen et al. in 2023, plans to test evening blue-blocking eyewear in euthymic or inter-episode outpatients with bipolar disorder. Its aim is mood and sleep stabilization rather than treatment of an active hospitalized manic episode.

That population differs from Ottawa's in several important ways. People at home control more of their evening light environment, face less intensive concurrent treatment, and may use the glasses as a routine over a longer maintenance period. Those differences could make an effect easier or harder to detect. A protocol reports a hypothesis and a design, not efficacy results, so it cannot yet resolve the question.

Practical feasibility also deserves attention. A 2025 qualitative analysis from the Ottawa study found that participants generally understood the biological rationale and were reasonably willing to use the glasses. It also described stigma around wearing tinted eyewear on a psychiatric ward, the novelty of research participation during mania, and lighting conditions outside participants' control. These are useful trial-design lessons, but qualitative acceptability cannot establish symptom benefit.

Outside bipolar disorder, the sleep evidence offers only indirect support. A randomized trial by Bigalke et al. in healthy adults tested evening blue-light blocking glasses with subjective and objective sleep outcomes, but the reported sleep effects were ambiguous. Healthy-adult sleep results cannot be used to infer treatment of mania.

What to do with amber glasses if you have bipolar disorder

Blue-light blocking glasses are not a validated treatment for bipolar mania and should never replace urgent clinical assessment, prescribed medication, or a crisis plan during escalating mania. A manic episode can impair judgment quickly; a pair of amber lenses is a poor substitute for medical care.

For someone who is stable between episodes, wearing amber lenses in the evening may be a low-cost way to reduce short-wavelength light before bed. The circadian rationale is credible, and some people may find that a consistent evening routine supports sleep. The evidence does not show that the glasses prevent bipolar episodes, stabilize mood, or abort mania. Treat that use as a sleep-hygiene experiment, not an antimanic therapy.

The best available blinded trial found no benefit for acute inpatient mania. Blue-light blocking remains plausible circadian hygiene and an unproven bipolar treatment.

If light-based treatment is part of a bipolar care plan, discuss timing and monitoring with the clinician managing the disorder. Bright light therapy has stronger trial evidence for bipolar depression, while blue-light blocking glasses still need adequately measured outpatient trials before anyone can promise more than a plausible mechanism.